Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Lamotrigine for Gabapentin Resistant Neuralgic Pain


Published on

  • Be the first to comment

  • Be the first to like this

Lamotrigine for Gabapentin Resistant Neuralgic Pain

  1. 1. LAMOTRIGINE FOR GABAPENTIN RESISTANT NEUROPATHIC PAIN Víctor Whizar-Lugo, Teresa Figueroa-García, Roberto Cisneros-Corral, Roberto Estrada-Coronado, Claudia Solar-Labastida. Servicios Profesionales de Anestesiología y Clínica de Dolor. Centro Medico del Noroeste. Tijuana BC, México 22320. IINTRODUCTIONNTRODUCTION NEUROPATHIC PAIN is an intriguing entity that may have different underlying mechanisms. Currently remains as the most difficult pain condition to study, to fully understand, and to treat. There are four categories of drugs that can be named ¨first choice¨ of treatment for neuropathic pain: antidepressants, antiepileptics, opioids, and local anesthetics. Other drugs listed to treat this type of pain are NMDA receptor antagonists, baclofen, levodopa, clonidine, nonsteroidal anti-inflammatory drugs, and topical local anesthetics and topical capsaicin. There is no magic drug to release the suffer of those unfortunates patients with any form of neuropathic pain. Although some researchers claimed well to excellent response to gabapentin plus antidepressants, there is a group of patients in whom the available medications give moderate analgesia to no pain improvement at all. Lamotrigine (figure 1), is a novel anticonvulsant that have been used as monotherapy and add-on drug in epilepsy, has also been reported to be useful in neuropathic pain (1, 2). Its mode of action is through the inhibition of the release of glutamate, possibly by stabilizing the neural membrane through blocking activation of voltage-sensitive sodium channels. There is little information on lamotrigine efficacy to treat neuropathic pain states refractory to agents such as carbamazepine, gabapentin and antidepressants. The purpose of the present study was to examine the potential analgesic effect of crescendo doses of oral lamotrigine in patients with diverse forms of neuropathic pain non- responding to gabapentin. MMETHODETHOD Twenty-five consecutive Mexicans patients with severe neuropathic pain of several etiologies, who were taking gabapentin from 1200 mg up to 2400 mg daily, were asked to participate in an approved protocol to receive crescendo doses of lamotrigine in order to treat their pain complaint. The method was explained to each patient and their relative, and the written consent form signed. We used the ad-on method, keeping the initial dose of gabapentin, and adding increasing dose of dispersible lamotrigine, starting at 25 mg twice a day. The dose was augmented 75 mg a day for further two weeks, followed by weekly increments to 100, 150, 200, 300, 400, 500, and 600 mg daily. Lamotrigine augmentations were based on pain response and side effects. As soon as the patient report 50% of pain improvement, gabapentin was slowly reduced
  2. 2. until discontinued. If the patient pain response was poor, gabapentin was continued or even increased, and well as lamotrigine. All cases were monitored weekly at the office, until good pain relieve was achieved (VAS 5 or less), followed by telephone calls/office visits every week until end of follow- up. Blood test were done monthly. RRESULTSESULTS All but two patients were able to finish the study. One patient dropped out due to protocol violation and another because of no medical reasons. Adequate pain relief was obtained in 17 patients. Six cases did not respond or had severe lamotrigine side effects. Twelve out of 23 patients were able to stop gabapentin, and 11 cases remained on gabapentin + lamotrigine. In this last group only 5 patients had significant pain improvement. Initial visual analogue scale (i-VAS ) of the 23 patients was 9.1 ± 2.3 versus final visual analogue scale (f-VAS) of 3.4 ± 2.0 (< 0.05). Table 1 shows demographic data, and the results of the 23 patients who finished the protocol. They are grouped by neuropathic pain categories to allow comparison between groups. Table 2 shows the analgesic response by pain etiology groups. There were no alterations on blood analysis Daily lamotrigine median dose in all cases was 451 ± 75.5 mg (DNP 400 ± 53, PHN 425 ± 58, TGN 500 ± 44, PIHRNP 500 ± 28, and CRNP 425 ± 106). Those patients who were able to cease gabapentin, were receiving daily lamotrigine median dose of 475 ± 76 mg (range 300 – 550), compared to patients taking the mixture lamotrigine + gabapentin who received a median dose of lamotrigine of 500 ± 76 mg and median dose of gabapentin 999 mg. There was no significative difference between lamotrigine doses on either group (p> 0.01). Table 1. Patients demographic data, pain etiology, anticonvulsivants dose, pain improvement and side effects Case Sex/Age Diagnosis i-GP dose f-GP dose f-LTG dose i-VAS vs f-VAS Side effects 1 F – 55 DNP 2400 None 350 7 – 3 No 2 F - 57 DNP 2400 600 350 8 – 2 No 3 M - 67 DNP 1600 None 400 10 – 2 Headache, dizziness 4 M – 70 DNP 1600 None 400 9 – 2 No 5 M – 72 DNP 900 None 500 8 – 2 Nausea 6 F – 76 DNP 1600 None 450 7 – 3 No 7 F – 76 DNP 1200 2000 400 9 – 7 Ataxia, vomiting 8 M – 56 PHN 2400 None 500 8 – 2 Moderate rash 9 M – 55 PHN 2000 None 375 9 – 2 No 10 F - 56 PHN 2000 2400 450 10 – 6 Severe rash, ataxia
  3. 3. 11 F – 76 PHN 2400 900 400 9 – 2 No 12 F – 77 PHN 1200 None 300 7 – 2 No 13 M - 83 PHN 2000 2400 500 9 – 7 No 14 M – 62 TGN 2400 2400 500 10 – 8 Blurred vision, dizziness, vomit 15 F – 62 TGN 2000 None 500 10 – 3 No 16 M – 84 TGN 2400 2400 500 10 – 2 No 17 M – 73 TGN 2400 1200 600 10 – 4 No 18 M – 67 TGN 2400 1200 500 10 – 2 No 19 F - 45 CRNP 2400 1600 350 9 – 6 Severe nausea 20 F – 57 CRNP 1800 None 500 8 – 2 Nausea, rash 21 M – 34 PIHRP 2400 None 500 8 – 1 No 22 M – 40 PIHRP 2000 None 550 9 – 3 No 23 M - 42 PIHRP 2400 2400 500 8 – 6 No DNP=Diabetic neuropathy, PHN=Postherpetic neuralgia, TGN=Trigeminal neuralgia, CRNP= Cancer related neuropathic pain, PIHRNP=Post inguinal hernia repair neuropathic pain. i-GP= Initial gabapentin dose, f-GP= Final gabapentin dose, f-LTG= Final lamotrigine dose i-VAS= Initial VSA, f-VAS= Final VSA In blue are patient responders, In bold are patients who did not response Table 2. Pain improvement by neuropathic pain etiology Pain Etiology n Cases n Patients with pain improvement n Patients without Pain Improvement n cases able to stop GP Lamotrigine median dose Diabetic neuropathy 7 6 1 5 400 ± 53 (350 – 500) Post herpetic neuralgia 6 4 2 3 425 ± 78 (300 – 500) Trigeminal neuralgia 5 4 1 1 500 ± 44 (500 – 600) Post inguinal hernia repair neuropathic pain 3 2 1 2 500 ± 28 (500 – 550) Cancer related neuropathic pain 2 1 1 1 425 ± 106 (350 – 500) TOTAL 23 17 6 12 451 ± 75 (300 – 600)
  4. 4. D i s c u s i o nD i s c u s i o n Lamotrigine, a new anticonvulsivant drug, have been approved to treat patients with epilepsy. In addition, it have been used in many others disorders like absence, atypical absence, myoclonic seizures, bipolar illness, and neuropathic pain. Intractable pain disorders like short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) have responded to lamotrigine 125 to 200 mg daily. It also reduces peripheral neuropathy symptoms in HIV/AIDS patients, in central post- stroke pain, trigeminal neuralgia, phantom limb pain, stump hypersensitivity (1, 3, 4) Although lamotrigine plays an important role as an adjuvant medicine or main therapeutic drug in patients with neuropathic pain, there is little information on its use for gabapentin resistant neuropathic pain. Even though our study is an open label trial using different neuropathic pain conditions that were not responding to gabapentin, the results are quite convincing that some patients may have excellent to moderate analgesia using either lamotrigine alone or lamotrigine plus gabapentin. Daily median lamotrigine dose in all cases was 451 ± 75.5 mg (DNP 400 ± 53, PHN 425 ± 58, TGN 500 ± 44, PIHRNP 500 ± 28, and CRNP 425 ± 106). There was no statistical difference between those patients who were able to cease gabapentin (lamotrigine median dose 475 ± 76 mg), compared to patients taking the mixture of lamotrigine + gabapentin (lamotrigine median dose 500 ± 76 mg). Pain response in these two groups was similar (i-VAS 8.3, f-VAS 2.25 ± 0.6 compared to i- Fig 2. Analgesia vs. lamotrigine dose 9.1 9.3 9.3 8.9 7.6 6.4 4.5 3.6 3.4 0 2 4 6 8 10 0 25 75 100 200 300 400 500 600 Crescendo lamotrigine dose in mg/day MeanPainIntensity (V.A.S.) 37.3 % pain reduction (p< 0.05)
  5. 5. VAS 9.2, f-VAS 4.7 ± 2.3). The overall pain response was statistically significant; i-VAS was 9.1 ± 2.3 versus f-VAS 3.4 ± 2.0 (p < 0.05). In the DNP group, one out of seven patients did no respond to gabapentin 1200 plus lamotrigine 400 mg due to severe lamotrigine side effects. The rest of this group had excellent analgesia and five were able to withdraw gabapentin. Luria and coworkers (2) reported 18 patients with painful diabetic neuropathy who responded to 200 mg up to 400 mg of lamotrigine and recommended that even higher dose may lead to a better response. Postherpetic neuralgia response was similar to DNP; two out of 6 patient developed lamotrigine side effects with poor analgesia. Four cases in this group developed side effects, in one instance those effects were intense; a 55 years old men who was taking 550 mg of lamotrigine reacted with severe rash that disappear after reducing lamotrigine to 375 mg daily. In the TGN group there was a patient who did not responded to 500 mg of lamotrigine. This patient was taking 2400 mg of gabapentin a day, and suffering frequent intense pain crisis. Lamotrigine crescendo dose up to 500 mg a day resulted in no pain improvement but side effects that needed to withdraw lamotrigine. Four patients with TGN responded well; one responded to 500 mg of lamotrigine without taking gabapentin, and five patients had excellent analgesia using the mixture of gabapentin-lamotrigine. These results are opposed to animal’s research suggesting that gabapentin rather than lamotrigine may be a superior treatment for trigeminal pain (5). Nevertheless, others researchers have found that 400 mg of lamotrigine relieve pain in most patients suffering essential TGN, with even better pain response in those with TGN concomitant with multiple sclerosis (6). Zakrzewska and coworkers (7) suggested that lamotrigine may be an effective drug for refractory Tic doloreux, but highlighted the necessity to address concerns about chronic use as monotherapy. The patients with neuropathic pain due to cancer and surgical nerve damage pain response were variable. Neuropathic pain secondary to a nerve constriction is a well- known technique to study neuropathic pain in animals (8). Surgical nerve damage during inguinal hernia restoration has been described in the literature, and has the same pathophysiology that animals nerve constriction pain. Surgical exploration aiming to release the constricted nerve usually fails and, on the contrary, it intensifies pain. Collins and cols. were able to fully reverse the pain behavior (paw-withdrawal threshold) of rats with neuropathic pain produced by ligatures of the sciatic nerve, which were receiving 30 mg/kg twice daily of oral lamotrigine. (8). In our study, two out of three patients had excellent analgesia using 500 mg of lamotrigine. In such cases, lamotrigine seems to be a better approach to relieve neuropathic pain. As it is showed on figure 2, the analgesic effect of lamotrigine requires time to allow slowly titration, in order to avoid severe reactions. It is obvious that adequate analgesia (50% or more from baseline level) was achieved after most patients reached 3000 t0 400 mg a day. The usual analgesic maintenance dose was 300 mg to 500 given in two or three divided doses. Some cases may require higher doses up to 600 mg daily. A therapeutic plasma concentration range has not been established, so, a crescendo dosing of lamotrigine should be based on therapeutic response vs. side effects.
  6. 6. The commonest side-effects whit lamotrigine include headache, nausea, dizziness, diplopia, ataxia, rash and tremor. Described uncommon sicknesses are blurred vision, somnolence, and vomiting. Very rare side effects include acute kidney or liver failure, drug-induced pseudolymphoma, neutropenia, thrombocitopenia, disseminated intravascular coagulation. There are cases reports of serious rashes requiring hospitalization and discontinuation of treatment have been reported in association with lamotrigine. Tolerance to lamotrigine has been well documented in elderly people. Daily dose from 75 to 300 mg as monotherapy, and 25-700 mg for add-on therapy for a median duration of 24.1 and 47.4 weeks respectively, produced lower incidence of drug- related adverse effects than carbamazepine or phenytoin. Patients on lamotrigine reported incidences of drowsiness, rash and nonsignificant headache that was half of those experienced by patients taking carbamazepine monotherapy. Lamotrigine sickness was common in this study (34.7%); four patients had severe side effects, and in other four cases those effects were minor. These drug reactions disappeared lowering the dose. ConclusionsConclusions Several authors are currently establishing the effectiveness and safeness of lamotrigine as a long-term therapeutic agent in neuropathic pain. Lamotrigine in doses ranging up to 600 mg/day has demonstrated efficacy in a variety of neuropathic pain states refractory to gabapentin. Those patients can be treated either by slowly switching gabapentin to lamotrigine or by using both drugs. Careful, slow dose titration and monitoring for adverse side effects are mandatory when using this agent. ReferencesReferences 1. McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. Clin J Pain 2000; 321-326. 2. Luria Y, Brecker C, Daud D, Ishay A, Eisenberg E. Lamotrigine in the treatment of painful diabetic neuropathy: A randomized, placebo-controlled study. Progress in Pain Research and Manage 2000:16;857-862. 3. D’Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology 2001;57:1723-1725. 4. Attal N. Pharmacologic treatment of neuropathic pain. Acta neurol belg 2001;101:53-64. 5. Christensen D, Gautron M, Guilbaud model of trigeminal neuropathic pain. Pain 2001;93:147-153. 6. Lunardi G, Leandri M, Albano C, Cultrera S, Fracassi M, Rubino V, Favale E. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997;48:1714-1717. 7. Zakrzewska JM, Chaudhry Z, Nurmikko TJ. Et als. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997;73:223-230.
  7. 7. 8. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensations like those seen in man. Pain 19988;33:87-107. 9. Collins SD, Clayton NM, Nobbs M, Bountra C. The effect of lamotrigine and morphine on neuropathic pain in the rat. Progress in Pain Research and Manage 2000:16;281-285. Figure 1. Lamotrigine